. 2022 Jun 14;13:913283. doi: 10.3389/fneur.2022.913283
Copyright © 2022 Czarnowska, Tarasiuk, Zajkowska, Wnuk, Marona, Nowak, Słowik, Jamroz-Wiśniewska, Rejdak, Lech, Popiel, Rościszewska-Żukowska, Perenc, Bartosik-Psujek, Świderek-Matysiak, Siger, Ciach, Walczak, Jurewicz, Stasiołek, Kania, Dyczkowska, Kalinowska-Łyszczarz, Galus, Walawska-Hrycek, Krzystanek, Chojdak-Łukasiewicz, Ubysz, Pokryszko-Dragan, Kapica-Topczewska, Chorąży, Bazylewicz, Mirończuk, Kulikowska, Kochanowicz, Białek, Stolarz, Kubicka-Bączyk, Niedziela, Warmus, Adamczyk-Sowa, Podlecka-Piçtowska, Nojszewska, Zakrzewska-Pniewska, Jasińska, Zaborski, Milewska-Jȩdrzejczak, Zwiernik, Zwiernik, Potemkowski, Brola and Kułakowska.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Figure 2.
The number of adverse events reported by individual patients with MS treated with DMTs in Poland.